Your browser doesn't support javascript.
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.
Okumura, Nobumasa; Tsuzuki, Shinya; Saito, Sho; Hattori, Shin-Ichiro; Takeuchi, Junko S; Saito, Tomoya; Ujiie, Mugen; Hojo, Masayuki; Iwamoto, Noriko; Sugiura, Wataru; Mitsuya, Hiroaki; Ohmagari, Norio.
  • Okumura N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tsuzuki S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ssaito@hosp.ncgm.go.jp.
  • Hattori SI; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Takeuchi JS; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Saito T; Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ujiie M; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Hojo M; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwamoto N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sugiura W; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
J Infect Chemother ; 28(9): 1340-1343, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1799832
ABSTRACT
The Omicron variant of severe acute respiratory syndrome coronavirus 2 has multiple amino acid mutations in its spike proteins, which may allow it to evade immunity elicited by vaccination. We examined the neutralising activity and S1-IgG titres in patients with breakthrough infections caused by the Omicron variant after two doses of vaccination. We found that neutralising activity was significantly lower for the Omicron variant than for the Wuhan strain. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2022.04.018

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2022.04.018